Moderna Inc (MRNA)vsNervGen Pharma Corp. (NGEN)
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
NGEN
NervGen Pharma Corp.
$2.19
+1.16%
HEALTHCARE · Cap: $250.53M
Smart Verdict
WallStSmart Research — data-driven comparison
NGEN leads profitability with a 0.0% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).
MRNA
Avoid21
out of 100
Grade: F
NGEN
Avoid16
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Intrinsic value data unavailable for NGEN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Trading at 18.2x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : NGEN
NGEN has a balanced fundamental profile.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : NGEN
The primary concerns for NGEN are Price/Book, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while NGEN is a value play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
NGEN generates stronger free cash flow (-6M), providing more financial flexibility.
Bottom Line
MRNA scores higher overall (21/100 vs 16/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
NervGen Pharma Corp.
HEALTHCARE · BIOTECHNOLOGY · USA
NervGen Pharma Corp. (NGEN) is an innovative biotechnology company dedicated to addressing critical unmet medical needs in neurodegenerative diseases with its proprietary nerve regeneration technology platform. The company focuses on developing groundbreaking therapeutics that aim to restore nerve function in conditions such as multiple sclerosis and spinal cord injuries. By advancing its clinical trials and expanding its intellectual property portfolio, NervGen is strategically positioned to capitalize on the growing demand for effective neurological treatments, presenting substantial growth potential and value creation opportunities for institutional investors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?